

## **MBC Pharma Inc. Awarded a SBIR Phase II Grant to Investigate Novel Compound for Multiple Myeloma**

Aurora, CO – October 27, 2008 - MBC Pharma Inc., a privately held biopharmaceutical company announced today, that it has been awarded an \$758,000 phase II Small Business Innovation Research (SBIR) grant from the U.S. National Institutes of Health (NIH). MBC will use this 2-year grant to further develop Company's lead compound MBC-11 towards clinical testing as a treatment for Multiple myeloma. "Prior to receiving this award MBC Pharma Inc. had successfully completed four separate Phase I SBIR/STTR grants; that work demonstrated efficacy of MBC-11 in animal models of multiple myeloma, breast cancer induced bone metastasis and prostate cancer induced bone disease and pain. " said Dr. Alexander Karpeisky, CSO and the Principal Investigator on the SBIR grant. "We are grateful that the SBIR program offers continued support and recognizes the potential benefit that MBC technology can offer for many types of bone disease."

"Our proprietary approach to bone targeting is to join known bone-seeking drug to chemotherapeutic via a safe, biodegradable linker. This enables previously unattainable levels of drug at the site of bone lesions. This grant will let us develop more effective therapies, designed to deliver anti-cancer drugs to bone while also providing a potent bone-protecting ingredient, for cancer-induced bone diseases, such as those associated with multiple myeloma." added Dr. Shawn Zinnen, VP of R&D.

### **About MBC Pharma**

MBC Pharma is a privately held pre-clinical-stage pharmaceutical company developing bone targeted therapeutics for serious diseases and conditions of bone with an oncology focus. MBC Pharma is planning to submit its first IND application in the first quarter of 2009 and subsequently initiate Phase I trials with its first-in-class compound MBC-11.

For information on MBC Pharma please contact Dr. Alexander Karpeisky or Dr. Shawn Zinnen at 720-859-4041.

MBC Pharma, Inc.  
<http://www.mbcpharma.com>